Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

universal donor expanded TGF-beta-imprinted NK cells

A preparation of ex vivo expanded, universal donor, transforming growth factor-beta (TGF-beta; TGF-b) imprinted natural killer (NK) cells, with potential cytolytic and antineoplastic activities. Upon administration, the universal donor expanded TGF-beta-imprinted NK cells may directly lyse cancer cells. These cells also secrete pro-inflammatory cytokines and further stimulate a systemic immune response against cancer cells. TGF-beta imprinting during NK cell activation and expansion decreases NK cell sensitivity to TGF-beta suppression and promotes NK cell cytokine hypersecretion, specifically of interferon-gamma (IFNg) and tumor necrosis factor-alpha (TNFa), and enhances NK cytotoxicity. TGF-beta is a potent immunosuppressive cytokine that inhibits the anti-tumor responses of NK cells and T cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic TGFBi expanded NK cells
UD TGF-betai NK Cells
universal donor TGF-beta imprinted expanded NK cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search